Safety and Pharmacokinetic Characteristics of DP-R206(Vitamin D3) in Healthy Adult Volunteers
- Registration Number
- NCT01577849
- Lead Sponsor
- Alvogen Korea
- Brief Summary
The purpose of this study is to compare the pharmacokinetic characteristics of DP-R206 (150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) and Vitamin D3 (24,000 IU Vitamin D3 , qd) after oral administration in healthy adult volunteers.
- Detailed Description
The number of patient is thirty-six. Patients were randomly assigned either a Vitamin D3 tablet(24,000 IU Vitamin D3, qd) first, DP-R206(150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) Second or DP-R206(150mg Ibandronate / 24,000 IU Vitamin D3 complex tablet, qd) first, Vitamin D3 tablet(24,000 IU Vitamin D3 , qd) second.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
- 20 to 55 years of healthy volunteers
- Hypersensitivity Reaction about Ibandronate or other drugs(aspirin, antibiotics)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Vitamin D3 Vitamin D3 - DP-R206 DP-R206 -
- Primary Outcome Measures
Name Time Method Composite of pharmacokinetics 24, -18, -12, -6, 0(predose), 1, 4, 6, 8, 10, 16, 24, 36, 48, 72, 96, 120 hours post-dose Cmax, AUClast
- Secondary Outcome Measures
Name Time Method Composite of pharmacokinetics 24, -18, -12, -6, 0(predose), 1, 4, 6, 8, 10, 16, 24, 36, 48, 72, 96, 120 hours post-dose AUCinf, tmax, t½β
Trial Locations
- Locations (1)
Chonbuk national University Hospital
🇰🇷Jeonju, Chonbuk, Korea, Republic of